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Abstract  Mesalamine  is  a  common  treatment  for  Crohn’s  disease,  and  can  be  rarely  associ-
ated with  myocarditis  through  a  mechanism  of  drug  hypersensitivity.  We  present  the  case  of
a 19-year-old  male  who  developed  chest  pain  two  weeks  after  beginning  mesalamine  therapy.
The electrocardiogram  showed  slight  ST-segment  elevation  with  upward  concavity  in  the  infer-
olateral leads;  blood  tests  demonstrated  elevated  troponin  I  and  the  echocardiogram  revealed
moderately  depressed  left  ventricular  systolic  function  with  global  hypocontractility.  Cardiac
magnetic  resonance  imaging  conﬁrmed  the  diagnosis  of  myocarditis,  revealing  multiple  areas
of subepicardial  ﬁbrosis.  The  onset  of  symptoms  after  mesalamine,  and  improvement  of  chest
pain, cardiac  biomarkers  and  left  ventricular  systolic  function  after  discontinuing  the  drug,
suggest that  our  patient  suffered  from  a  rare  drug-hypersensitivity  reaction  to  mesalamine.
© 2012  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Miocardite  induzida  pela  mesalamina  após  o  diagnóstico  de  doenc¸a de  Crohn  --  relato
de  um  caso  clínico
Resumo  A  mesalamina  é  um  tratamento  comum  para  a  doenc¸a  de  Crohn,  associando-se  de
forma rara  à  miocardite  aguda,  através  de  uma  reac¸ão  de  hipersensibilidade  ao  fármaco.  Os
autores apresentam  o  caso  clínico  de  um  jovem  de  19  anos  com  aparecimento  de  dor  torá-
cica duas  semanas  após  ter  iniciado  tratamento  com  mesalamina  para  a  doenc¸a  de  Crohn.
loaded from http://http://www.elsevier.pt, day 14/02/2014. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.O eletrocardiograma  mostrou  um  discreto  supradesnivelamento  do  segmento  ST,  de  concavi-
dade ascendente,  nas  derivac¸ões  infero-laterais;  as  análises  revelaram  elevac¸ão  da  troponina  I
e o  ecocardiograma  exibiu  uma  depressão  moderada  da  func¸ão  sistólica  do  ventrículo  esquerdo,
por hipocontractilidade  global.  A  ressonância  magnética  cardíaca  conﬁrmou  o  diagnóstico  de
miocardite,  evidenciando  múltiplas  áreas  de  ﬁbrose  subepicárdica.  O  início  dos  sintomas  após  o
comec¸o da  mesalamina  e  a  melhoria  da  dor  torácica,  biomarcadores  cardíacos  e  func¸ão  sistólica
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ventricular  esquerda  após  a  suspensão  do  medicamento,  sugerem  que  o  nosso  paciente  teve
uma reac¸ão  rara  de  hipersensibilidade  à  mesalamina.
© 2012  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos reservados.
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esalamine  (5-aminosalicylic  acid)  is  a  well-known  treat-
ent  for  inﬂammatory  bowel  disease,  often  used  as  the
rst-line  drug.  Although  rare,  adverse  cardiac  reactions
ue  to  mesalamine  have  been  described  in  the  literature,
nd  include  pericarditis,  myocarditis,  coronary  vasculitis
nd  left  ventricular  dysfunction.1--4 We  report  a  case  of
esalamine-induced  myocarditis  in  a  patient  with  a  recent
iagnosis  of  Crohn’s  disease.
ase report
 19-year-old  male  with  no  relevant  medical  history,  besides
aving  been  diagnosed  two  weeks  previously  with  Crohn’s
isease  for  which  he  was  medicated  with  mesalamine  1500
g  twice  a  day  and  budesonide  9  mg  daily,  was  admitted
o  the  local  hospital  with  retrosternal  chest  pain  radiating
o  the  left  arm.  He  reported  no  accompanying  symptoms
nd  no  relieving  or  aggravating  factors  were  identiﬁed.  The
atient  had  no  reported  previous  infection.  The  physical
xamination  was  unremarkable  and  there  were  no  signs
f  hemodynamic  instability  or  heart  failure.  The  initial
2-lead  electrocardiogram  revealed  sinus  rhythm  and  slight
T-segment  elevation  with  upward  concavity  in  leads  I,  II,  III,
VF  and  V3--V6  (Figure  1).  As  laboratory  tests  showed  ele-
ated  cardiac  necrosis  biomarkers  (troponin  I  9.1  ng/ml),  he
as  transferred  to  our  hospital  for  cardiological  evaluation.
ollowing  admission  to  the  cardiac  care  unit,  he  mentioned
ome  episodes  of  chest  pain  which  improved  after  treat-
ent  with  aspirin.  Repeated  blood  tests  demonstrated  a
urther  increase  in  cardiac  biomarkers  (peak  troponin  I  27.3
g/ml  and  peak  total  CK  915  IU/l)  accompanied  by  elevation
f  NT-proBNP  (6413  pg/ml)  and  inﬂammatory  parameters
C-reactive  protein  130  mg/l,  15  800  leukocytes).  Remodel-
ng  therapy  with  ACE  inhibitors  and  beta-blockers  was  also
ntroduced,  due  to  the  moderately  depressed  left  ventricu-
ar  systolic  function  (ejection  fraction  of  38%)  seen  on  the
ransthoracic  echocardiogram,  with  global  hypocontractil-
ty,  although  more  noticeable  in  the  posterior,  inferior  and
ateral  walls  (Figure  2).  Cardiac  magnetic  resonance  imag-
ng  (MRI)  with  delayed  gadolinium  enhancement  revealed
ultiple  areas  of  myocardial  ﬁbrosis,  mainly  subepicardial,
uggesting  a  non-ischemic  pattern  (Figure  3).  There  was  no
ign  of  myocardial  infarction  and  the  patient  was  therefore
iagnosed  with  acute  myocarditis.In  view  of  mesalamine’s  cardiovascular  toxicity  as
escribed  in  the  literature,  this  drug  was  discontinued
hortly  after  admission.  The  patient  remained  asymptomatic
hereafter  and  laboratory  tests  were  favorable  (NT-proBNP
i
l
m
m05  pg/ml  and  troponin  I  0.13  ng/ml  at  discharge).  Elec-
rocardiograms  showed  progressive  resolution  of  ST-segment
levation  and  the  echocardiogram  was  repeated  one  week
ater,  demonstrating  improvement  in  left  ventricular  systolic
unction  (ejection  fraction  of  45%).
iscussion
lassic  myocarditis  refers  to  inﬂammation  of  the  heart  mus-
le  as  a  result  of  exposure  to  either  discrete  external  antigen
riggers,  such  as  viruses,  bacteria,  parasites  or  drugs,  or
o  internal  triggers  such  as  autoimmune  activation  against
elf-antigens.  Drugs  can  act  as  a  direct  toxic  agent  (anthra-
yclines  and  cocaine)  or  by  a  hypersensitivity  reaction,  as  is
hought  to  be  the  case  with  mesalamine  and  other  medica-
ions  (clozapine,  sulfonamides,  cephalosporins,  penicillins
nd  tricyclic  antidepressants).5
Cardiac  disease  can  be  associated  with  Crohn’s  dis-
ase  as  an  extraintestinal  manifestation  of  inﬂammatory
owel  disease  or  as  a  consequence  of  drug-induced  side
ffects.1--4 Myocarditis  associated  with  mesalamine  is  a
are  but  potentially  serious  phenomenon,  generally  occur-
ing  2--4  weeks  after  the  initial  exposure  to  the  drug,
lthough  presentation  may  be  delayed  over  years,  especially
f  steroids  are  used  concomitantly.6 Mesalamine’s  mech-
nism  of  action  is  not  fully  understood,  but  it  includes
nhibition  of  the  cyclooxygenase  pathway,  inducing  an  anti-
nﬂammatory  effect  in  the  colon.  The  exact  mechanism  for
esalamine-induced  myocardial  inﬂammation  is  not  clearly
dentiﬁed,  but  it  is  thought  to  be  a  hypersensitivity  reaction
ather  than  a  cytotoxic  effect.1,2 One  proposed  mechanism
s  humoral-mediated  hypersensitivity,  in  which  antibodies
ormed  against  mesalamine  cross-react  with  cardiac  tis-
ue  causing  inﬂammation.6 The  diagnosis  of  hypersensitivity
yocarditis  is  supported  by  two  facts:  inﬂammation  wors-
ns  if  mesalamine  is  reintroduced  during  the  acute  phase,1
nd  resolution  of  symptoms  occurs  within  one  week  after
rug  discontinuation,  as  has  been  described  in  all  reported
ases.1--4 Eosinophilic  inﬁltration  of  the  myocardium  on
ndomyocardial  biopsy  has  also  been  described,7 which
eems  to  conﬁrm  the  link  between  mesalamine  and  hyper-
ensitivity  myocarditis.
In  our  case,  the  onset  and  resolution  of  symptoms  were
imilar  to  those  reported  in  the  literature.  Soon  after
iscontinuing  mesalamine,  our  patient  evolved  well,  with
rogressive  falls  in  cardiac  biomarkers  and  improvement
n  left  ventricular  systolic  function.  Considering  this  evo-
ution  and  the  fact  that  there  was  no  previous  infection,
esalamine-induced  myocarditis  was  considered  to  be  the
ost  likely  diagnosis.
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Figure  1  Electrocardiogram  on  day  of  chest  pain  onset:  sinus  rhythm  and  slight  ST-segment  elevation  with  upward  concavity  in
leads I,  II,  III,  aVF  and  V3--V6.
Figure  2  Echocardiogram  in  parasternal  short-axis  view  showing  moderately  depressed  left  ventricular  systolic  function  (ejection
fraction of  38%),  with  global  hypocontractility,  although  more  obvious  in  the  posterior,  inferior  and  lateral  walls  (A  --  diastole;  B  --
systole).
Document downloaded from http://http://www.elsevier.pt, day 14/02/2014. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.Figure  3  Cardiac  magnetic  resonance  imaging  with  myocardial  sup
multiple areas  of  subepicardial  myocardial  ﬁbrosis,  mainly  in  the  infepression  after  contrast.  Late  gadolinium  enhancement  reveals
rior  and  lateral  walls,  in  short-axis  (A)  and  4-chamber  views  (B).
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onclusion
his  case  illustrates  the  importance  of  eliciting  a  thorough
edical  history  and  being  aware  of  the  timing  when  new
edications  are  started.  It  is  imperative  that  any  new  onset
f  chest  pain  in  the  setting  of  inﬂammatory  bowel  disease
reated  with  mesalamine  should  be  evaluated  via  cardiac
nzymes,  electrocardiogram,  echocardiogram  and  possibly
ardiac  MRI  to  rapidly  diagnose  any  complication  caused  by
ither  the  inﬂammatory  bowel  disease  itself  or  an  adverse
rug  reaction.
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